This article has been cited by other articles in PMC.
Full text is available as a scanned copy of the original print version. Get a printable copy (PDF file) of the complete article (1.6M), or click on a page image below to browse page by page. Links to PubMed are also available for Selected References.
These references are in PubMed. This may not be the complete list of references from this article.
O'Rourke PP, Crone RK, Vacanti JP, Ware JH, Lillehei CW, Parad RB, Epstein MF. Extracorporeal membrane oxygenation and conventional medical therapy in neonates with persistent pulmonary hypertension of the newborn: a prospective randomized study. Pediatrics. 1989 Dec;84(6):957–963.[PubMed]
Yusuf S, Collins R, Peto R, Furberg C, Stampfer MJ, Goldhaber SZ, Hennekens CH. Intravenous and intracoronary fibrinolytic therapy in acute myocardial infarction: overview of results on mortality, reinfarction and side-effects from 33 randomized controlled trials. Eur Heart J. 1985 Jul;6(7):556–585.[PubMed]
Freedman B. Equipoise and the ethics of clinical research. N Engl J Med. 1987 Jul 16;317(3):141–145.[PubMed]
Geller NL, Pocock SJ. Interim analyses in randomized clinical trials: ramifications and guidelines for practitioners. Biometrics. 1987 Mar;43(1):213–223.[PubMed]
Fleming TR, Harrington DP, O'Brien PC. Designs for group sequential tests. Control Clin Trials. 1984 Dec;5(4):348–361.[PubMed]
O'Brien PC, Fleming TR. A multiple testing procedure for clinical trials. Biometrics. 1979 Sep;35(3):549–556.[PubMed]
Dillman RO, Seagren SL, Propert KJ, Guerra J, Eaton WL, Perry MC, Carey RW, Frei EF, 3rd, Green MR. A randomized trial of induction chemotherapy plus high-dose radiation versus radiation alone in stage III non-small-cell lung cancer. N Engl J Med. 1990 Oct 4;323(14):940–945.[PubMed]
Peto R, Pike MC, Armitage P, Breslow NE, Cox DR, Howard SV, Mantel N, McPherson K, Peto J, Smith PG. Design and analysis of randomized clinical trials requiring prolonged observation of each patient. I. Introduction and design. Br J Cancer. 1976 Dec;34(6):585–612.[PMC free article][PubMed]
Pawitan Y, Hallstrom A. Statistical interim monitoring of the Cardiac Arrhythmia Suppression Trial. Stat Med. 1990 Sep;9(9):1081–1090.[PubMed]
Freedman LS, Spiegelhalter DJ. Comparison of Bayesian with group sequential methods for monitoring clinical trials. Control Clin Trials. 1989 Dec;10(4):357–367.[PubMed]
Pocock SJ, Hughes MD. Estimation issues in clinical trials and overviews. Stat Med. 1990 Jun;9(6):657–671.[PubMed]
Fleming TR, Watelet LF. Approaches to monitoring clinical trials. J Natl Cancer Inst. 1989 Feb 1;81(3):188–193.[PubMed]
Henderson WG, Fisher SG, Weber L, Hammermeister KE, Sethi G. Conditional power for arbitrary survival curves to decide whether to extend a clinical trial. Control Clin Trials. 1991 Apr;12(2):304–313.[PubMed]
Ware JH, Muller JE, Braunwald E. The futility index. An approach to the cost-effective termination of randomized clinical trials. Am J Med. 1985 Apr;78(4):635–643.[PubMed]
Hampton JR, Julian DG. Role of the pharmaceutical industry in major clinical trials. Lancet. 1987 Nov 28;2(8570):1258–1259.[PubMed]
Volberding PA, Lagakos SW, Koch MA, Pettinelli C, Myers MW, Booth DK, Balfour HH, Jr, Reichman RC, Bartlett JA, Hirsch MS, et al. Zidovudine in asymptomatic human immunodeficiency virus infection. A controlled trial in persons with fewer than 500 CD4-positive cells per cubic millimeter. The AIDS Clinical Trials Group of the National Institute of Allergy and Infectious Diseases. N Engl J Med. 1990 Apr 5;322(14):941–949.[PubMed]
Pocock SJ, Thompson SG. Primary prevention trials in cardiovascular disease. J Epidemiol Community Health. 1990 Mar;44(1):3–6.[PMC free article][PubMed]
Articles from The BMJ are provided here courtesy of BMJ Group